首页> 美国卫生研究院文献>Respirology Case Reports >Topical mitomycin‐C as an adjuvant to multimodal endoscopic treatment for tracheobronchial stenosis secondary to endobronchial tuberculosis
【2h】

Topical mitomycin‐C as an adjuvant to multimodal endoscopic treatment for tracheobronchial stenosis secondary to endobronchial tuberculosis

机译:局部丝裂霉素-C作为多峰内镜治疗的辅助气管支气管狭窄其辅助结核结核病

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Tracheobronchial stenosis secondary to endobronchial tuberculosis (TSTB) is a rare but debilitating complication of endobronchial tuberculosis (EBTB). Topical mitomycin‐C (TMC) has been successfully utilized to restore airway patency and to prevent recurrence of TSTB, although little is known about its exact efficacy. Here, we report the biggest case series to date involving seven patients who received TMC as part of multimodality endoscopic treatment for TSTB with varying levels of success. All patients presented with dyspnoea during or after treatment completion for pulmonary tuberculosis (PTB). Four patients had short‐segment concentric membranous TSTB while two patients had concurrent bronchomalacia. Another one patient had a thick fibrotic band adjacent to luminal opening. We hypothesize that TMC is more efficacious in short membranous stenosis without concurrent bronchomalacia and/or thick fibrotic bands. More studies are needed to bridge the current gaps in knowledge regarding the optimal role and benefits of TMC for TSTB patients.
机译:中间核心结核病(TSTB)的气管辐条狭窄是一种罕见但令人衰弱的内核天线结核(EBTB)的并发症。局部丝霉素-C(TMC)已成功利用以恢复气道通畅,并防止TSTB的复发,但很少有关于其确切功效。在这里,我们报告了迄今为止涉及七名患者的最大案例系列,作为TSTB的多地形内窥镜治疗的一部分,其成功水平不同。所有患者在治疗肺结核(PTB)的治疗完成期间或后患有呼吸困难。四名患者有短段同心膜TSTB,而两名患者患有两种患者并发支气管疾病。另一个患者具有厚纤维间带,腔开口相邻。我们假设TMC在短膜狭窄中更有效,没有同时支气管疾病和/或厚的纤维化带。需要更多的研究来弥合关于TSTB患者TMC的最佳作用和益处的知识中的当前差距。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号